2026 Leads Physicians 
PM360
SEPTEMBER 21, 2023
The MFPs will be announced publicly in September 2024 and go into effect on January 1, 2026. CMS negotiation may lead to additional savings for beneficiaries and for the Medicare program. After this period, CMS will begin to include physician-administered drugs covered under Part B in the program.
European Pharmaceutical Review
FEBRUARY 8, 2023
It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7 Breyanzi is approved for DLBCL, and a label expansion is anticipated for expansions into marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) in 2026 and 2028, respectively.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JULY 26, 2022
NPC is a rare inherited disease resulting from the body's inability to conduct intracellular transport of cholesterol and other lipids, leading to the abnormal accumulation of these substances in various bodily tissues, including brain tissue.
Clarivate
OCTOBER 25, 2023
The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.
Clarivate
APRIL 24, 2023
Oak Street has 169 locations across 21 states and expects to nearly double its size to 300 centers by 2026. VillageMD’s rollup continued with a March 3 announcement that it was acquiring Starling Physicians, a Connecticut-based physician group, expanding its footprint to 680 practice locations in 26 markets.
Clarivate
APRIL 18, 2024
In 2023, Humana’s care delivery component CenterWell launched a senior-centered “ Primary Care Anywhere ” program for in-home primary care in Georgia and Louisiana (where Humana leads the MA sectors) and increased senior membership in value-based home care models nationwide to more than 840,000. Source: News reports and company releases.
Pharmaceutical Technology
JANUARY 10, 2023
The erosion of Januvia is due to patent expiry in that had been expected in 2022 and physicians’ preference for sodium-glucose linked transporter-2 inhibitor (SGLT-2I) therapies such as Farxiga (dapagliflozin) and Jardiance (empagliflozin) due to their ability to improve glycemic control and address cardiorenal comorbidities.
Expert insights. Personalized for you.
111 
Let's personalize your content